Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Mutations in GATA2 are rare in juvenile myelomonocytic leukemia

Elliot Stieglitz, Y. Lucy Liu, Peter D. Emanuel, Robert P. Castleberry, Todd M. Cooper, Kevin M. Shannon, Mignon L. Loh

Blood (2014) 123 (9): 1426–1427.

https://doi.org/10.1182/blood-2013-11-531079

Published: 2014

Journal Articles

Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia

Elliot Stieglitz, MD, Y. Lucy Liu, MD, PhD, Peter D. Emanuel, MD, Robert P. Castleberry, MD, Todd Michael Cooper, Kevin Shannon, MD, Mignon L. Loh, MD

Blood (2013) 122 (21): 1526.

https://doi.org/10.1182/blood.V122.21.1526.1526

Published: 2013

Journal Articles

CREB Deficiency: A Potential Critical Factor for Selective GM-CSF Hypersensitivity in Juvenile Myelomonocytic Leukemia.

Y. Lucy Liu, MD, PhD, Priyangi A Malaviarachchi, BS, Shelly Y. Lensing, MS, Robert P. Castleberry, MD, Peter Dean Emanuel, MD

Blood (2009) 114 (22): 2604.

https://doi.org/10.1182/blood.V114.22.2604.2604

Published: 2009

Journal Articles

Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia

Sophie Archambeault, Nikki J. Flores, Ayami Yoshimi, Christian P. Kratz, Miriam Reising, Alexandra Fischer, Peter Noellke, Franco Locatelli, Petr Sedlacek, Christian Flotho, Marco Zecca, Peter D. Emanuel, Robert P. Castleberry, Charlotte M. Niemeyer, Peter Bader, Mignon L. Loh

Blood (2008) 111 (3): 1124–1127.

https://doi.org/10.1182/blood-2007-06-093302

Published: 2008

Includes: Supplemental data

Journal Articles

Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study.

Robert P. Castleberry, MD, Mignon L. Loh, MD, Nalini Jayaprakash, April Peterson, Vicky Casey, Myron Chang, PhD, Brigitte Widemann, MD, Peter D. Emanuel, MD

Blood (2005) 106 (11): 2587.

https://doi.org/10.1182/blood.V106.11.2587.2587

Published: 2005

Journal Articles

Decitabine, a Potential Targeted Therapeutic for Juvenile Myelomonocytic Leukemia.

Y. Lucy Liu, MD, PhD, Peter Dean Emanuel, MD, Robert P. Castleberry, MD

Blood (2005) 106 (11): 2516.

https://doi.org/10.1182/blood.V106.11.2516.2516

Published: 2005

Journal Articles

The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease

Christian P. Kratz, Charlotte M. Niemeyer, Robert P. Castleberry, Mualla Cetin, Eva Bergsträsser, Peter D. Emanuel, Henrik Hasle, Gabriela Kardos, Cornelia Klein, Seiji Kojima, Jan Stary, Monika Trebo, Marco Zecca, Bruce D. Gelb, Marco Tartaglia, Mignon L. Loh

Blood (2005) 106 (6): 2183–2185.

https://doi.org/10.1182/blood-2005-02-0531

Published: 2005

Journal Articles

Evidence for PTEN Deficiency in Juvenile Myelomonocytic Leukemia.

Y. Lucy Liu, MD, PhD, Likang Xu, MD, Robert P. Castleberry, MD, Peter Dean Emanuel, MD

Blood (2004) 104 (11): 3428.

https://doi.org/10.1182/blood.V104.11.3428.3428

Published: 2004

Journal Articles

Rapamycin -- a Potential Mechanistically Targeted Therapeutic for Juvenile Myelomonocytic Leukemia.

Y. Lucy Liu, MD, PhD, Robert P. Castleberry, MD, Peter Dean Emanuel, MD

Blood (2004) 104 (11): 2378.

https://doi.org/10.1182/blood.V104.11.2378.2378

Published: 2004

Journal Articles

Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors: Presented in part at the Thirty-Ninth American Society of Hematology Meeting, San Diego, CA, December 5-9, 1997.

Peter D. Emanuel, Richard C. Snyder, Tonya Wiley, Balaganesh Gopurala, Robert P. Castleberry

Blood (2000) 95 (2): 639–645.

https://doi.org/10.1182/blood.V95.2.639

Published: 2000

Journal Articles

Mutations of the NF1 Gene in Children With Juvenile Myelomonocytic Leukemia Without Clinical Evidence of Neurofibromatosis, Type 1

Lucy E. Side, Peter D. Emanuel, Brigit Taylor, Janet Franklin, Patricia Thompson, Robert P. Castleberry, Kevin M. Shannon

Blood (1998) 92 (1): 267–272.

https://doi.org/10.1182/blood.V92.1.267.413a31_267_272

Published: 1998

NARROW

Mutations in GATA2 are rare in juvenile myelomonocytic leukemia

Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia

CREB Deficiency: A Potential Critical Factor for Selective GM-CSF Hypersensitivity in Juvenile Myelomonocytic Leukemia.

Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia

Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study.

Decitabine, a Potential Targeted Therapeutic for Juvenile Myelomonocytic Leukemia.

The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease

Evidence for PTEN Deficiency in Juvenile Myelomonocytic Leukemia.

Rapamycin -- a Potential Mechanistically Targeted Therapeutic for Juvenile Myelomonocytic Leukemia.

Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors: Presented in part at the Thirty-Ninth American Society of Hematology Meeting, San Diego, CA, December 5-9, 1997.

Mutations of the NF1 Gene in Children With Juvenile Myelomonocytic Leukemia Without Clinical Evidence of Neurofibromatosis, Type 1

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only